Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Clinical trial NCT03876028 · TERMINATED
Trial details
- NCT number
- NCT03876028
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-11
- Primary completion
- 2021-11-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.